Background
Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients with moderate-to-severe atopic dermatitis (AD). We report the sustained impact of lebrikizumab monotherapy, over 52 weeks and between visits, on the frequency of itch and sleep loss symptoms, as assessed by Patient-Oriented Eczema Measure (POEM), in patients with moderate-to-severe AD.
Methods
In ADvocate1 and ADvocate2, Week-16 lebrikizumab responders (EASI75 or IGA 0/1 with ≥ 2-point improvement and without rescue medication) were randomized to lebrikizumab every 2 weeks (Q2W), every 4 weeks (Q4W), or placebo for 36 weeks. This pooled analysis reports improvement from Week 16 to 52 in patients achieving POEM response 0 (no days) or 1 (1–2 days) for Items 1 (itch) and 2 (sleep disturbance) for the lebrikizumab Q2W and Q4W treatment arms. Observed (excluding data collected after treatment discontinuation, rescue medication use, or patient transfer to escape arm) results were reported.
Results
At Week 16, for lebrikizumab Q2W and Q4W, 35.9% (
n
= 37/103) and 39.3% (
n
= 42/107) of patients responded 0 or 1 to Item 1 of POEM (Itch) and 12.6% (
n
= 13/103) and 12.1% (
n
= 13/107) responded 0. A total of 66.0% (
n
= 68/103) and 72.6% (
n
= 77/106) of patients responded 0 or 1 to Item 2 of POEM (Sleep) and 37.9% (
n
= 39/103) and 44.3% (
n
= 47/106) responded 0, respectively. By Week 52, for lebrikizumab Q2W and Q4W, 44.6% (
n
= 29/65) and 48.0% (
n
= 36/75) responded 0 or 1 to Item 1 of POEM (Itch), and 21.5% (
n
= 14/65) and 18.7% (
n
= 14/75) of patients responded 0. A total of 83.1% (
n
= 54/65) and 78.4% (
n
= 58/74) responded 0 or 1 to Item 2 of POEM (Sleep), and 67.7% (
n
= 44/65) and 59.5% (
n
= 44/74) responded 0, respectively.
Conclusion
Weekly POEM responses for itch and sleep disturbance remained stable between doses and visits, and continued to improve from Week 16 through 52, in lebrikizumab-treated patients, demonstrating consistent improvement over time for key AD symptoms.
Trial Registration Numbers
ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).